Newsroom
Promising progress on a breakthrough therapy for severe heart failure
Chronic Heart Failure (CHF) is a clinical syndrome associated with high morbidity and mortality globally, which seriously affects people's quality of life. More than 12 million people suffer from CHF in China and the United States alone. Patients with the most advanced symptoms (classified as New York Heart Association (NYHA) class IV), which account for 10% to 15% of all CHF patients, are mostly bedridden and experience symptoms even while at rest. The annual mortality rate for these patients is over 50%, which is considerably higher than that for many types of cancer. Currently, standard treatment for CHF mainly reduces the workload of the heart by lowering blood pressure or slowing the beating rate of the heart.
close
Forbes China interviewed Zensun’s CEO - Dr. Mingdong Zh...
Zensun (Shanghai) Sci & Tech Co., Ltd. is a biopharmaceutical company focused on the development of innovative bio-therapeutic ...